The aberrant expression of LMTK3 andAKT has been observed in several types of human's cancer 2-6.However, recent studies have demonstrated that inhibition ofLMTK3 2, and pathway (AKT and/or mTOR) deletion, restoresensitivity to anti-estrogen treatment in breast cancer cells 4.These proteins can therefore, play a critical role in the cancertherapy development 5,6, AKT1 and LMTK3 havecharacteristics necessary for design of effective and reliable smalldrug molecule. This evidence concerns the gene LMTK3 and breast cancer.